The current study was conducted in buffalo at the Government Livestock Farm, Sirsa Road, Hisar and nearby areas after prior approval from Institutional Animal Ethics Committee (Registration: 1669/GO/ReBiBt-S/Re-L/12/CPCSEA), COVS, LUVAS (Hisar) vide approval number- VCC/IAEC/2022/624 − 51; dated- 10-05-2022. The distribution of animals in each group was done randomly to avoid any inter-farm differences under each treatment group. The study was conducted on a total of ninty four (n = 94) normal cycling buffaloes (> 90 days post-partum) between 2nd and 6th parity with 3–4 body condition score out of 5 scale. .
Also, only those buffaloes were considered which had surpassed 90 days post-partum with no manifestation of estrus signs. The buffaloes having history of any pathology of the reproductive organs and aberrant cervico-vaginal mucus discharge, were not part of this study. The feeding practices followed were according to the availability of seasonal green fodder with required concentrates as per milk yield of the individual animal. The animals were provided with 1% mineral mixture and free access to drinking water. The buffaloes were examined twice at 11 days apart through trans-rectal ultrasonography (USG) to ascertain the presence of CL. Furthermore, the blood was also collected on both days of examination to confirm the cyclicity through plasma progesterone concentration. The buffalo had plasma progesterone concentrations > 1 ng/ml on either of the sample was considered as cyclic.
Experimental Design
The buffaloes under the study were randomly distributed into two treatment groups. These buffaloes in respective groups were subjected to administration of single PGF2α and PGF2α followed by EB as categorized below:
Group-I (n = 40)
The buffaloes in this group (n = 40) received a single dose of injection PGF2α (Cloprostenol sodium, 500µg, Zolcol®, Carus Pharmaceuticals Ltd. India) intramuscular (IM) on day 0 and fixed time artificial insemination (FTAI) was performed twice at 72 and 84h of PGF2α injection. The schematic presentation of treatment protocol is described in Fig. 1. Blood sampling for hormonal estimation and USG was carried out before the treatment (day 0), day 1, at the time of first-AI, and day 5 and 12 post-AI.
Group-II (n = 54)
The buffaloes of this group (n = 54) received a single dose of PGF2α (Cloprostenol sodium, 500µg, Zolcol®, Carus Pharmaceuticals Ltd. India) IM on day 0 followed by injection Estradiol Benzoate (1mg, PregHeat®, Virbac Pharmaceuticals India Ltd.) 24h after the injection of PGF2α IM and FTAI was performed twice at 72 and 84h of PGF2α treatment (48 and 60h after injection of Estradiol benzoate; EB). The schematic presentation of treatment protocol is described in Fig. 1. Blood sampling for hormonal estimation and USG was carried out before the treatment (day 0), day 1, at the time of first-AI, and day 5 and 12 post-AI.
Estrus response
The estrus signs showed by the individual animal were recorded during morning and evening hours for confirmation of estrus. The most common estrus signs recorded were frequent micturition, vulvar swelling, mucus discharge, restlessness, bellowing, standing heat, uterine tone, sniffing/licking, aggression and mounting on others (if observed). The buffalo showing various intensities of estrus response were recorded individually. Doka/TET (Temporary engorgement of teats) before the actual onset of estrus was also noted for each animal. Intensity of estrus was described on the basis of total score. Total score for each animal observed was classified into three categories such as weak (1–11), moderate (12–22) and intense (23–33) as described in Table 1 (Layek et al. 2011). The estrus induction rate (%) was calculated for each estrus synchronization protocol as percentage of buffaloes which exhibited the signs of estrus out of all buffaloes subjected to estrus synchronization protocol.
Table 1
Classification of intensity of estrus response on the basis of symptoms exhibited by the buffaloes
Estrus Symptom | Frequency of expression during an estrus period |
Weak (Score 1) | Moderate (Score 2) | Intense (Score 3) |
Standing heat | < 9 | 9–14 | > 14 |
Mounting on others | < 9 | 9–14 | > 14 |
Frequent micturition | < 3 | 3–4 | > 4 |
Vulvar swelling | + | ++ | +++ |
Mucus discharge | Absent | Slight | Copious |
Restlessness | Mild | Moderate | Pronounced |
Bellowing | Very seldom | Occasional | Often |
Uterine tone | + | ++ | +++ |
Licking/Sniffing | < 6 | 6–8 | > 8 |
Doka/TET | + | ++ | +++ |
Aggression | Mild | Moderate | Pronounced |
Ultrasonography (USG)
The trans-rectal ultrasonography for a subset of 15 buffaloes from each group was performed using ultrasound machine (SonoScape®; SonoScape Medical Corp.) before the treatment (day 0), on day 1, at the time of first-AI, and day 5 and 12 post-AI. The follicular and luteal structures of each ovary with their dimensions were recorded for each buffalo subjected to USG. The diameter of largest follicle (LF) on day 0 and day 1, Pre-ovulatory follicle (POF) diameter on day of AI and area of corpus luteum (CL) on day 0 was recorded. The diameter of the follicles/CL was determined by measurement of the largest and widest diameter of the follicles/CL and thereafter, average diameter calculated (Pierson and Ginther, 1985). Additionally, the CL area was recorded on day 5 and 12 post-AI also. The CL area was calculated using formula π X (diameter of CL/2)2. Ultrasonography was performed at day 45 post-AI for pregnancy diagnosis.
Blood sampling and hormone analysis
Blood sampling for hormonal estimation was carried out before the treatment (day 0), day 1, at the time of first-AI and on day 5 and 12 post-AI. Blood samples were collected from jugular vein of buffalo (n = 15 of each group) in 10 ml vacutainer vial containing sodium heparin as anticoagulant. Immediately after blood collection, samples were transferred to the laboratory for separation of plasma. Plasma separation was performed by using centrifuge machine at 1500xg for 15 minutes. Aliquots of plasma were taken in eppendorf tube and stored at -20°C until estimation of hormones.
Plasma progesterone (P4) and estradiol-17β (E2) concentrations were estimated by using a commercially available Direct Immunoenzymatic Assay Kit (CALBIOTECH, USA) while, Plasma insulin like factor-1 (IGF-1) concentration was estimated by using commercially available Sandwich ELISA kit (BT-LAB, Korain biotech).
Statistical analysis
Statistical software IBM SPSS Statistics 24.0 (SPSS Inc., Chicago, IL, USA) was used for making the statistical comparison of the data. The data obtained from both the groups were analysed using one-way ANOVA for comparison of different hormonal concentrations and USG data of all days within each group. Chi-square test was used for comparison of percentage data (FSCR and estrus response) of all groups. Unpaired Student’s T-test was used for comparison of data between pregnant and non-pregnant animals of each group. The values were defined significant at a P-value ≤ 0.05. The values were expressed as mean ± standard error or percentage.